The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
Caleres, Inc.
CAL · the NYSE · USD · Market cap $473M
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price12.82 USD at the 19 Nov 2026 close
- Fair value24.92. Our model only; no analyst estimate to cross-check.
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.48)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $22.79 to $27.50, base estimate $24.92 (screen dated 2026-11-19).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.48, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Caleres, Inc. holds its Markup at $12.82. Consolidating, no directional conviction, held for 4 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 4 days |
| Price at the screen | $12.82 |
| Valuation | N/A trailing · 5.52 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.72 |
Five Screens: CAL's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 183.67% | Below 33% | Fail |
| Interest-bearing cash | 6.14% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Caleres,'s business is in a permissible area, but its interest-bearing debt is about 184% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CAL's ethical verdict changes
Today CAL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 49% discount to our $24.92 fair value, weak competitive moat, 8.70% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 48.6% discount to the base estimate.
Where our models see it going: fair-value estimate $24.92, with a range of $22.79 to $27.50, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 5.5xcheap for a company growing this fast |
| EPS, trailing | -0.21 |
| EPS, forward | 2.16 |
| Revenue growth | +8.7%steady growth |
| Profit margin | -0.2%currently unprofitable |
| Return on equity | -1.6%not currently earning a positive return on equity |
| Dividend yield | 2.13% |
| Debt to equity | 1.46a meaningful debt load worth watching |
| Beta | 0.72steadier than the market |
| Moat | WEAK |
| Market cap | $473M |
CAL-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $17.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-27 | Gil Cisneros | Democrat | sell | 100K–250K |
| 2026-10-23 | Gil Cisneros | Democrat | buy | 250K–500K |
| 2026-10-19 | Gil Cisneros | Democrat | buy | 250K–500K |
| 2026-10-09 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-08 | Ro Khanna | Democrat | sell | 50K–100K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $12.06 | +13.0% | · | $1,130 | +13.0% |
| 2 months | $12.52 | +8.9% | · | $1,089 | +8.9% |
| 3 months | $9.35 | +45.8% | $0.07 | $1,465 | +46.5% |
| 6 months | $13.37 | +1.9% | $0.14 | $1,030 | +3.0% |
| 1 year | $14.10 | -3.3% | $0.21 | $982 | -1.8% |
| 2 years | $31.83 | -57.2% | $0.49 | $444 | -55.6% |
| 3 years | $22.91 | -40.5% | $0.77 | $629 | -37.1% |
| 5 years | $26.17 | -47.9% | $1.33 | $572 | -42.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CAL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.